Im Gun-Il
Integrative Research Institute for Regenerative Biomedical Engineering, Dongguk University, Goyang, South Korea.
Bone Joint Res. 2021 Feb;10(2):134-136. doi: 10.1302/2046-3758.102.BJR-2020-0517.R1.
The high prevalence of osteoarthritis (OA), as well as the current lack of disease-modifying drugs for OA, has provided a rationale for regenerative medicine as a possible treatment modality for OA treatment. In this editorial, the current status of regenerative medicine in OA including stem cells, exosomes, and genes is summarized along with the author's perspectives. Despite a tremendous interest, so far there is very little evidence proving the efficacy of this modality for clinical application. As symptomatic relief is not sufficient to justify the high cost associated with regenerative medicine, definitive structural improvement that would last for years or decades and obviate or delay the need for joint arthroplasty is essential for regenerative medicine to retain a place among OA treatment methods. Cite this article: 2021;10(2):134-136.
骨关节炎（OA）的高患病率，以及目前缺乏用于OA的疾病缓解药物，为再生医学作为OA治疗的一种可能方式提供了理论依据。在这篇社论中，总结了再生医学在OA中的现状，包括干细胞、外泌体和基因，并阐述了作者的观点。尽管人们对此兴趣浓厚，但迄今为止，几乎没有证据证明这种方式在临床应用中的有效性。由于症状缓解不足以证明再生医学相关的高昂成本合理，对于再生医学而言，实现持续数年或数十年的明确结构改善，并避免或推迟关节置换的需求，对于其在OA治疗方法中占据一席之地至关重要。引用本文：2021；10（2）：134 - 136。
